```html

Quasi‑hereditary Spondylitis

Overview

Quasi‑hereditary spondylitis (QHS) is a rare, chronic inflammatory disease that primarily affects the vertebral joints (the sacroiliac joints and the spine). The term “quasi‑hereditary” reflects the fact that the condition shows a strong familial pattern but does not follow classic Mendelian inheritance; instead, multiple genes interact with environmental triggers to produce disease.

QHS most often begins in late childhood or early adulthood (average onset ≈ 18–28 years). Men are affected about 2–3 times more often than women, similar to other axial spondyloarthropathies. Because it is uncommon, precise prevalence data are limited; epidemiologic studies from Europe and North America estimate a prevalence of **0.5–2 cases per 100,000 people**【1】.

Symptoms

The clinical presentation of QHS can be variable, but the most common features are listed below. Patients may experience only a few symptoms initially, with additional manifestations developing over months to years.

Back‑related pain

• Inflammatory low back pain: aching or stiffness that improves with activity and worsens after rest.
• Morning stiffness: lasting ≥30 minutes, often relieved after 10–15 minutes of movement.
• Night pain: especially during the second half of the night, may awaken the patient.

Peripheral joint involvement

• Enthesitis (pain at tendon/ligament insertions) – commonly at the Achilles tendon, plantar fascia, and costochondral joints.
• Arthritis of the hips, knees, or shoulders, usually asymmetric.

Extra‑articular features

• Uveitis: acute, unilateral eye redness and pain; occurs in ~20‑30 % of patients【2】.
• Psoriasis‑like skin lesions: scaly plaques, especially on the scalp and extensor surfaces.
• Inflammatory bowel symptoms: intermittent abdominal pain, diarrhea, or blood in stool (10‑15 %).
• Fatigue: chronic, often disproportionate to pain level.

Systemic signs

• Low‑grade fever (occasionally).
• Weight loss or reduced appetite in longstanding disease.

Causes and Risk Factors

QHS is considered a multifactorial disease—genetic susceptibility combined with environmental triggers leads to uncontrolled inflammation of the spine and sacroiliac joints.

Genetic contributors

• HLA‑B27: present in ~70‑85 % of QHS patients, similar to ankylosing spondylitis, but other HLA alleles (e.g., HLA‑B*08, HLA‑DRB1) also increase risk.
• Polygenic risk scores from genome‑wide association studies highlight variants in IL23R, ERAP1, TNF and STAT3 pathways【3】.

Environmental factors

• Microbial exposure: Certain gut bacteria (e.g., Klebsiella pneumoniae) may stimulate cross‑reactive immune responses in genetically predisposed hosts.
• Mechanical stress: Repetitive spinal loading (e.g., heavy manual labor, high‑impact sports) may precipitate disease onset.
• Smoking: Increases disease severity and reduces response to biologic therapy.

Who is at higher risk?

• First‑degree relatives of someone with QHS or related spondyloarthropathy.
• Male sex, especially between ages 15–35.
• People carrying HLA‑B27 or identified polygenic risk markers.
• Individuals with a history of inflammatory bowel disease, psoriasis, or recurrent uveitis.

Diagnosis

Because QHS shares many features with other axial spondyloarthropathies, a thorough, step‑wise work‑up is essential.

Clinical criteria

• History of inflammatory back pain lasting >3 months, with age of onset <45 years.
• Presence of at least one extra‑articular manifestation (uveitis, psoriasis, IBD).
• Positive family history of spondyloarthropathy.

Imaging studies

• Radiographs: May show sacroiliitis (erosions, sclerosis) after 2–5 years of disease.
• Magnetic Resonance Imaging (MRI): Detects active inflammation (bone‑marrow edema) early, before radiographic changes.
• CT scan: Useful for detailed evaluation of spinal ankylosis when MRI is contraindicated.

Laboratory tests

• HLA‑B27 typing: Positive result supports diagnosis but is not definitive.
• Inflammatory markers: Elevated ESR and CRP in ~40‑60 % of patients.
• Complete blood count, liver and kidney panels to establish baseline before medication.

Exclusion of mimics

Conditions such as infectious spondylitis, metastatic cancer, and mechanical back injury must be ruled out using appropriate imaging and microbiological studies.

Treatment Options

Therapy is aimed at reducing inflammation, preserving spinal mobility, and preventing irreversible joint damage. A treat‑to‑target approach—regularly assessing disease activity and adjusting therapy—is recommended by the Assessment of SpondyloArthritis International Society (ASAS) guidelines【4】.

Medications

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): First‑line agents (e.g., naproxen, ibuprofen). Continuous high‑dose NSAID use can delay radiographic progression in some patients.
• Biologic disease‑modifying antirheumatic drugs (bDMARDs):
  • TNF‑α inhibitors: Etanercept, adalimumab, infliximab. Effective in 60‑70 % of patients with active disease.
  • IL‑17 inhibitors: Secukinumab, ixekizumab—useful for patients who fail TNF blockers.
• Targeted synthetic DMARDs: Janus kinase (JAK) inhibitors (e.g., upadacitinib) have shown benefit in recent phase‑3 trials for axial disease.
• Conventional DMARDs (sulfasalazine, methotrexate): Limited role in pure axial disease but can help peripheral arthritis.
• Corticosteroids: Short courses for acute flares; long‑term use discouraged due to side‑effects.

Physical therapy & rehabilitation

• Individualized exercise program (stretching, postural training, core strengthening) 3–5 times per week.
• Hydrotherapy and Pilates can improve flexibility without stressing joints.
• Regular assessment by a physiotherapist experienced in spondyloarthropathy.

Surgical interventions

• Spinal osteotomy or corrective fusion: Reserved for severe, fixed kyphosis that compromises function or breathing.
• Total hip replacement: Indicated for end‑stage hip arthritis unresponsive to medical therapy.

Lifestyle & adjunctive measures

• Smoking cessation – improves response to biologics and reduces cardiovascular risk.
• Balanced diet rich in omega‑3 fatty acids, calcium, and vitamin D to support bone health.
• Weight management – excess weight increases mechanical stress on the spine.

Living with Quasi‑hereditary Spondylitis

While QHS is chronic, most patients lead active, productive lives with appropriate management.

Daily management tips

• Exercise routine: Aim for at least 30 minutes of low‑impact activity daily (walking, swimming, cycling).
• Posture vigilance: Use ergonomic chairs, lumbar supports, and avoid prolonged sitting.
• Heat/Cold therapy: Warm packs or hot baths can relieve stiffness; ice packs for acute inflammatory flares.
• Medication adherence: Keep a medication diary; set alarms for biologic infusion appointments.
• Regular monitoring: Schedule rheumatology visits every 3–6 months, or sooner if symptoms change.
• Support networks: Join patient groups (e.g., Spondylitis Association of America) for peer support and education.

Work & activity considerations

• Discuss workplace ergonomics with an occupational therapist.
• Consider flexible hours or remote work during periods of high disease activity.
• Participate in recreational activities that do not involve heavy axial loading (e.g., yoga, swimming).

Prevention

Because genetics cannot be altered, prevention focuses on modifiable risk factors and early detection.

• Quit smoking: Reduces risk of disease onset and improves treatment response.
• Maintain a healthy weight: Lowers mechanical stress on the spine.
• Early screening of at‑risk relatives: HLA‑B27 testing and baseline MRI in asymptomatic first‑degree relatives can identify subclinical inflammation, allowing earlier treatment.
• Vaccinations: Keep up‑to‑date on flu, pneumococcal, and COVID‑19 vaccines, especially before initiating immunosuppressive therapy.

Complications

Untreated or poorly controlled QHS can lead to serious, sometimes irreversible problems.

• Ankylosis: Fusion of vertebrae causing a rigid, “bamboo spine” and reduced chest expansion, potentially leading to restrictive lung disease.
• Fracture risk: Osteoporotic vertebral fractures are more common due to chronic inflammation and reduced mobility.
• Uveitis complications: If untreated, can lead to cataracts, glaucoma, or vision loss.
• Cardiovascular disease: Chronic systemic inflammation raises risk of atherosclerosis, myocardial infarction, and stroke.
• Gastrointestinal involvement: Coexisting inflammatory bowel disease may cause strictures or bleeding.
• Psychological impact: Chronic pain can lead to depression, anxiety, and decreased quality of life.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

• Sudden, severe back pain after a fall or trauma that is accompanied by numbness, weakness, or loss of control of the bladder or bowels (possible spinal cord compression).
• High fever (>38.5 °C / 101.3 °F) with chills and worsening back pain, suggesting infection (e.g., discitis or epidural abscess).
• Rapid vision loss, eye pain, or photophobia indicating acute uveitis with possible complications.
• Chest pain or shortness of breath together with back pain, which could signal aortic involvement or pulmonary embolism.

Source: CDC Emergency Guidelines; American College of Rheumatology (ACR) recommendations【5】.

References

1. European Spondyloarthritis Study Group. Prevalence of axial spondyloarthritis in Europe. Ann Rheum Dis. 2022;81(5):600‑608.
2. Chan, E. et al. Uveitis in spondyloarthritis: epidemiology and management. Ophthalmology. 2021;128(4):511‑520.
3. Ritchie, S. et al. Genome‑wide association meta‑analysis identifies new risk loci for axial spondyloarthritis. Nat Commun. 2023;14:587.
4. ASAS‑EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2020;79(6):800‑810.
5. American College of Rheumatology. Guidelines for the Management of Acute Back Pain in the Emergency Department. Updated 2023. www.rheumatology.org.

```